GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (STU:A71) » Definitions » Deferred Tax

Ascendis Pharma AS (STU:A71) Deferred Tax : €4.8 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma AS Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Ascendis Pharma AS's change in deferred tax for the three months ended in Dec. 2024 was €1.1 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was €4.8 Mil.

Ascendis Pharma AS Deferred Tax Historical Data

The historical data trend for Ascendis Pharma AS's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Deferred Tax Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.37 5.38 7.30 4.84

Ascendis Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.79 2.51 0.23 1.02 1.09

Ascendis Pharma AS Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.8 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Deferred Tax Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (STU:A71) » Definitions » Deferred Tax
Comparable Companies
PCVX JAZZ SRPT TECH EXEL RVMD ROIV MDGL LEGN HALO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
ASND:USA ASND:Mexico A71:Germany A1SN34:Brazil
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Website
https://www.ascendispharma.com
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma AS Headlines

No Headlines